Source facts
FDA issued a warning letter to Hadassah Healing Oils Ltd concerning Unapproved New Drugs. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.
US FDA source recordWL · Warning Letter
Hadassah Healing Oils Ltd — FDA Warning Letter
Issued to Hadassah Healing Oils Ltd. Serious post-market compliance violation.
Issued
June 17, 2026Product
Unapproved New Drugs
Company
Hadassah Healing Oils Ltd
Review center
CDERStage
Final Decision
Assyro regulatory brief
FreeWhy did Hadassah Healing Oils Ltd receive an FDA warning letter?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1Subject: Unapproved New Drugs.
- 2Issuing office: Center for Drug Evaluation and Research (CDER).
- 3No closeout letter was listed in the source metadata at refresh time.
Suggested next step
Review the exact FDA warning letter, cited violations, requested corrections, and any later response or closeout before assessing current status.
Open the document workspaceFDA source document
Read the full FDA warning letter
FDA publishes this warning letter as a web document.
Open the exact FDA source to read the complete letter and verify its current response or closeout status.
Common questions about the Hadassah Healing Oils Ltd warning letter
What does this warning letter mean for Hadassah Healing Oils Ltd?
Serious post-market compliance violation. Public notice requiring prompt remediation. FDA issued this letter on June 17, 2026.
What happens after an FDA warning letter?
The firm is expected to respond in writing, normally within 15 working days, describing corrective actions and timelines. FDA verifies remediation — often through reinspection — and issues a closeout letter when violations are corrected. Unresolved warning letters can escalate to import alerts, seizure, or injunction.